Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class small molecule product candidates with broad potential benefit to patients
Science
Modulating validated and new pathways to develop novel therapeutics
News
November 18,
2021
Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
November 12,
2021
Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
November 10,
2021
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
Events
Monday,
November 22ND,
2021
at
10:00 AM
Eastern
Piper Sandler 33rd Annual Virtual Healthcare Conference
Listen: Webcast
Thursday,
November 18TH,
2021
at
8:00 AM
Eastern
Jefferies London Healthcare Conference
Listen: Webcast
Monday,
March 29TH,
2021
at
8:30 AM
Eastern
Tempest and Millendo Proposed Merger Investor Call
Listen: Webcast
Download: Proposed Merger of Tempest and Millendo [pdf]